Intraventricular neurocytomas: a systematic review of stereotactic radiosurgery and fractionated conventional radiotherapy for residual or recurrent tumors.

Abstract	To determine optimal treatment for recurrent or residual intraventricular neurocytomas (IVNs), a systematic review of PubMed and EMBASE was conducted comparing fractionated conventional radiotherapy (FCRT) versus stereotactic radiosurgery (SRS). Inclusion criteria included histological IVN documentation, at least 6 months of follow-up observation and described dose of FCRT or SRS administered. Descriptive statistical and Kaplan-Meier analyses were performed. The literature search yielded 451 articles. Sixteen studies met inclusion criteria. The local tumor control proportion was 93% and 88% in the SRS and FCRT subgroups, respectively. The relative risk (RR) of local recurrence was 0.57 less (95% CI: 0.21-1.57; log-rank p=0.85) and the RR of all-cause mortality was 0.23 less (95% CI: 0.05-1.05; log-rank p=0.22) in SRS subgroup compared to the FCRT subgroup but did not reach statistical significance. Recurrence was significantly associated with presence of histological atypia (log-rank p<0.001). Severe complications were lower in SRS subgroup (5.5% versus 7.5%, p=0.74); however, distant tumor recurrence was slightly lower in the FCRT subgroup (1.5% versus 5.5%, p=0.24). The role of SRS or FCRT in the management of residual or recurrent IVNs will continue to depend on the balance between the risks and benefits of SRS and FCRT until better quality data are available.
Authors	Roxanna M Garcia, Michael E Ivan, Taemin Oh, Igor Barani, Andrew T Parsa
Journal	Clinical neurology and neurosurgery (Clin Neurol Neurosurg) Vol. 117 Pg. 55-64 (Feb 2014) ISSN: 1872-6968 [Electronic] Netherlands
PMID	24438806 (Publication Type: Journal Article, Meta-Analysis, Review, Systematic Review)
Copyright	Published by Elsevier B.V.
Topics	Cerebral Ventricle Neoplasms (mortality, radiotherapy, surgery) Humans Kaplan-Meier Estimate Neoplasm Recurrence, Local (radiotherapy, surgery) Neoplasm, Residual (radiotherapy, surgery) Neurocytoma (mortality, radiotherapy, surgery) Radiometry Radiosurgery (adverse effects, methods) Survival Analysis Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!